Join the Scientific Update Newsletter

Impurities Guidelines

Permissible limits for impurities during clinical development has always been a grey area. Existing guidelines, specifically ICH Q3A only formally apply to marketed products. How factors such as duration of clinical trials have never been effectively addressed.

19 Close

Filter